Renovo Group plc was a biopharmaceutical company founded in 1998 and headquartered in Manchester, United Kingdom. It worked in the discovery and development of drugs to reduce scarring, improve wound healing and enhance tissue regeneration.London Regenerative Medicine Network – January 2007 Meeting Renovo does not currently have any marketed products. It aimed "to be first to market with a scar prevention pharmaceutical drug in the US and Europe" in approximately 2014. Following the failure of its last clinical candidate, Juvista, all 100 of Renovo's staff were laid off in 2011.Renovo Group founder to become Science Foundation Ireland's boss (9 January 2012). Manchester Evening News.Pharma Times Just 10% of workforce left at Renovo after Juvista failure (4 March 2011). Pharmatimes.com.
Although the company stopped all pharmaceutical development, it continued as a financial provider. In August 2014, Renovo Group plc was renamed Inspired Capital plc.Rename Plan for Renovo (16 July 2014). InsiderMedia.com
Products Renovo does not currently have any marketed products. Its development pipeline currently includes one drug in phase III clinical development, two in phase II clinical development, and numerous pre-clinical candidates.Renovo – Products
Drug Phase Action Juvista Failed"Pharma Times" Just 10% of workforce left at Renovo after Juvista failure (4 March 2011). Pharmatimes.com. Injecting into the wound margins around the time of surgery causes a prevention or reduction of scarring through the introduction of recombinant TGFβ3. Adaprev HaltedAshcroft, Jamie. (18 November 2011) "ProactiveInvestors" – Renovo ends Adaprev development (18 November 2011). Proactiveinvestors.co.uk. Injected at the time of surgery to prevent and reduce scarring and adhesions between the tendon and surrounding tissues following tendon repair. Prevascar HaltedAshcroft, Jamie. (16 April 2012) "ProactiveInvestor" Renovo ends Prevascar development (16 April 2012). Proactiveinvestors.co.uk. Injection into the wound margins around the time of surgery reduces scarring by suppressing of TGFβ1 and TGFβ2. Juvidex Renovo planned to partner with Juvidex as a cosmetic ingredient to improve skin appearance and to promote the healing of damaged skin. RN1005 Phase I Clinical trial RN1005 is an advanced preclinical candidate pharmaceutical, discovered by Renovo, targeting the Wnt pathway to reduce scarring and enhance tissue regeneration.
References
External links